Answers are grounded in this paper and cite their sources.
Randomized trial compares low-dose and high-dose radioiodine for thyroid cancer ablation, suggesting heightened initial success with high doses.
e18119 Background: Differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy. It is typically managed with thyroidectomy followed by remnant ablation using radio-iodine (RAI) therapy which reduces recurrence risk and facilitates follow up. Although high-dose RAI (100-150 mCi) has been the standard treatment, low-dose regimens (30-50 mCi) may reduce radiation exposure and toxicity, but their comparative efficacy in achieving ablation success and preventing recurrence remains uncertain. We performed a systematic review and meta-analysis of randomized controlled trials comparing low-dose versus high-dose radio-iodine for remnant thyroid ablation. Methods: A comprehensive search of PubMed, Cochrane library,and clinicaltrials.gov was conducted from inception until September, 2025.Data on ablation outcomes and long-term recurrence rate was extracted. Data was analyzed on R studio version 4.1.1, forest plots were generated using random effect model, and heterogeneity was assessed using I² statistics. Results: Sixteen randomized control trials including 4,047 patients (n=2,098 low dose; n=1,949 high dose) were analyzed. Initial ablation success was reported in 14 trials (n=3,385) and indicated that high-dose radio-iodine significantly improved initial ablation success compared to low-dose (RR: 0.93, 95% CI 0.89–0.98; P = 0.0083; I² = 40%). Long-term recurrence was reported in 8 studies including 2,983 participants. There was no statistically significant difference between low- and high-dose radioiodine (RR 0.94, 95% CI 0.63–1.42; P = 0.78), with high consistency across trials (I² = 0%). Conclusions: This meta-analysis demonstrates that high-dose radio-iodine statistically improves initial ablation success compared to low-dose in patients with differentiated thyroid carcinoma; however, long-term recurrence rates are similar between doses. These findings highlight that careful patient selection and further studies with standardized follow up are warranted to optimize dosing strategy.
No takes yet. Share an insight, caveat, or question.
Umer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: